SMC endorses five new therapies for NHS Scotland
Scottish cost regulators have approved funding for five new therapies on the NHS, offering new treatment options for a range of conditions.
Read More
Tag: velpatasvir
NICE nod for Gilead’s pan-genotypic hepatitis C therapy
Gilead’s pan-genotypic treatment for hepatitis C Vosevi has won the National Institute for Health and Care Excellence’s seal of approval for use on the NHS.
Read More
Darzalex, Epclusa will be funded on NHS Scotland
Patients in Scotland with multiple myeloma and those with some types of hepatitis C have won NHS access to new treatment options after the Scottish Medicines Consortium backed routine use of Janssen’s Darzalex and Gilead’s Epclusa.
Read More
US nod for Gilead’s pan-genotypic hep C pill
The US Food and Drug Administration has waved through Gilead’s new hepatitis C therapy Vosevi, offering adults with all genotypes of the condition a new treatment option in the form of three medicines in a single pill.
Read More
Final yes from NICE for Gilead’s Epclusa
The National Institute for Health and Care Excellence has now published final guidance endorsing Epclusa as an option for the treatment of adults with chronic hepatitis C genotype 1-6 infection on the NHS in England and Wales.
Read More
NICE clears Gilead’s pan-genotypic hep C drug Epclusa
The National Institute for Health and Care Excellence is endorsing Gilead’s pan-genotypic hepatitis C drug Epclusa for routine NHS use in England and Wales.
Read More
US clears Gilead’s pan-genotypic hepatitis C therapy
Gilead’s Sovaldi-based combination therapy for hepatitis C has been cleared for use by the US Food and Drug Administration to treat all six types of the virus, potentially eliminating the need for genotype testing.
Read More
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
